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& Abstract
Aim: The aim of this study was to prospectively assess the
prognostic value of initial pain intensity and its duration in
advanced cancer patients.
Methods: A prospective study was conducted in a sample of
patients with cancer requiring pain control. Patients under-
went standard analgesic strategies used in our palliative care
units. Pain intensity was measured at admission (T0) and after
successful dose titration or opioid/route switching within a
week (Ts). Patients were also asked about their pain intensity
reported 15 days before admission (T-15). Doses of opioids
and duration of opioid use were recorded.
Patients were also assessed for the presence of incident
pain, neuropathic pain, alcoholism, delirium, and symptom
intensity, including items representing psychological distress.
One week after or at time of stabilization (Ts), the opioid
response was clinically graded as follows: (1) good pain
control; (2) adequate pain control requiring more aggressive
opioid escalation; (3) adequate pain control associated with
the occurrence of adverse effects; (4) incapacity to achieve
pain control within a week. Opioid escalation indexes and
days for dose finding were also recorded.
Results: Pain intensity at T0 and at T-15, opioid doses,
duration of opioid therapy, and age were associated with
more complex analgesic therapies, which were effective in
almost all patients within a week.
Conclusion: High levels of pain intensity, often due to
previous undertreatment, are predictive of more complex
analgesic treatment. Opioid tolerance, as well as younger
age, may also play a role. &
Key Words: cancer pain, assessment tools, opioid response,
pain assessment, pain measurement, opioid, cancer, opioid
analgesics, pain intensity, prognostic factors
INTRODUCTION
The heterogeneity and complexity of patients with
cancer pain represent a relevant challenge for research-
ers. The possibility of grouping patients to predict their
analgesic response, possibly identifying patients with
cancer who are less likely to respond to standard
treatment, is of paramount importance.1 The Edmonton
Staging System (ESS) is prognostic tool, which has been
designed to enable researchers to speak a common
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language and to make meaningful generalization from
data of clinical trials. Subsequent versions of ESS
(revised ESS, rESS) have been proposed with the intent
to select patients with less problematic pain features,
requiring a shorter time to achieve stable pain control
and less complicated analgesic regimens.2
Several factors, such as neuropathic pain, incident
pain, psychological distress, or higher pain intensity,
have been identified to influence pain outcomes.3 From a
re-analysis of an observational study, a large number of
domains were identified, explaining only 16 to 24% of
the variability of the pain outcome.4 In particular, initial
pain intensity was found to be a strong predictor of pain
outcome, confirming data from a previous secondary
analysis.5 A high level of pain intensity “per se”,
however, does not seem to be clinically an intrinsic
factor, as it may possibly depend on several factors. For
example, it may result from a previous undertreatment,
which could be potentially resolved in a simple way and
could not influence the prognosis.6 The multicenter
nature of the study, with unselected settings using
different procedures of opioid titration and no clear
definition of some variables, could have influenced the
data. For instance, original data suggested a delayed
recourse to strong opioids in a substantial percentage of
patients.7 Thus, unplanned or nonhomogeneous meth-
ods of pain management may explain these findings. In
fact, in these studies, several days were needed to reach
relatively low doses of opioids despite low levels of pain
intensity. For example, patients with moderate–severe
pain achieved stable pain control after 8 to 22 days,
with doses of 48 to 72 mg of oral morphine equivalents.5
Using more intensive protocols in specialist palliative
care settings, the achievement of adequate pain control is
commonly obtained within 24 to 48 hours, indepen-
dently of the initial pain intensity.8–12 These observa-
tions suggest that a timelier opioid titration performed
in a specialistic setting can produce a rapid pain control,
minimizing the potential influence of initial pain inten-
sity. Rather, a previous undertreatment could be rele-
vant for pain outcome. Moreover, the inclusion of
patients with mild pain who are commonly not deemed
of changes in analgesic treatment may influence the
outcome. Therefore, the analysis should be performed in
patients who require some modification of the analgesic
treatment, particularly in patients with moderate–severe
pain.
The aim of this study was to prospectively assess the
influence of initial pain intensity and its duration in a
sample of patients who required changes in analgesic
treatment to control pain, according to a similar
protocol of opioid dose titration. The secondary out-
comes were to re-analyze the principal prognostic
factors assessed in literature using specific tools, as well
as the previous opioid therapy, in terms of doses and
duration.
PATIENTS AND METHODS
Study Design
This prospective study was conducted in a sample of
consecutive patients admitted to 2 acute pain relief and
supportive care units during an 18-month period. The
ethical committee of University of Palermo, Italy,
approved the study. All patients provided their informed
consent.
Patients
Inclusion criteria were adults; a diagnosis of chronic
cancer pain of moderate–severe intensity (> 4 on a
numerical scale 0-10); and receiving an analgesic phar-
macological treatment, which was unsuccessful at con-
trolling their pain.13 Exclusion criteria were an expected
short survival (< 1 month), and severe cognitive impair-
ment limiting the assessment.
Procedures
Consenting patients who met inclusion criteria were
assessed. At admission (T0), the average pain intensity
reported in the past 24 hours was measured using a
numerical scale choosing a number from 0 (no pain) to
10 (the worst pain imaginable). Patients were also asked
to recall their pain intensity about 15 days before
admission (T-15), the amount of analgesic used, and
how long they were using opioids at doses of oral
morphine dose equivalents ≥ 60 mg/day. Patients were
treated with opioids to balance analgesia and adverse
effects, eventually supported by symptomatic drugs,
according to department policy and routine protocols in
the units, previously reported in other studies.10 Briefly,
opioid treatment was individualized according to previ-
ous exposure and response, and tailored opioid titration
was performed with daily visits, according to the pain
intensity and patients’ needs. Changes of route of
administration were eventually performed according to
the needs, such as patients with nausea and vomiting,
which precluded the oral route. When adverse effects
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predominated despite supportive treatment, an opioid
switching was performed, using starting conversion
ratios previously described.14 Doses were subsequently
changed according to the clinical response. Opioid
dose stabilization (Ts) was considered the planned daily
dose that provided acceptable background analgesia
(≤ 4/10), with no more than 3 rescue doses as needed,
and acceptable adverse effect intensity. Data were
expressed in oral morphine equivalents.
Efficacy Measures
Patients were assessed for a series of variables. Principal
factors examined for opioid response included pain at
admission (T0), 15 days before admission (T-15), and
at time of stabilization (Ts) were the. Other factors
were also taken into consideration. The presence of
breakthrough pain was defined as an episode of severe
pain intensity, well distinguished from background pain
(at least 3 different points on a numerical scale 0-10).
Patients with an incident component due to movement
were specifically assessed. The presence of neuropathic
component was assessed by PainDETECT,15 which has
been found to have good discriminant validity in
patients with cancer.16,17 Delirium was assessed by
Confusion Assessment Method (CAM),18 and alcohol-
ism was assessed by CAGE questionnaire (cut-down,
annoyed, guilty, eye-opener).19 Symptom intensity was
assessed using the Edmonton Symptom Assessment
System (ESAS), which also includes 2 items representing
psychological distress.12
Opioid Response
One week after starting treatment or at time of
stabilization (Ts), the opioid response was clinically
graded as follows: (1) good pain control (≤ 4 on a
numerical scale 0-10) with minimal opioid escalation
and without relevant adverse effects; (2) adequate pain
control requiring more aggressive opioid escalation,
for example, doubling the doses in 4 days; (3)
adequate pain control associated with the occurrence
of adverse effects, requiring aggressive symptomatic
treatment or eventually opioid/route switching; (4)
incapacity to achieve an pain control or prevalence of
adverse effects within a week.9 The opioid escalation
index (OEI) was calculated as a percentage from the
initial dose at T0 to T1 (after 1 week), according to
the following formula: OEI%: [(x-y)/x]/days 9 100,
where x is dose at stabilization, and y is the dose at
admission. OEI in mg was calculated with the follow-
ing formula: (x–y)/days, as oral morphine equiva-
lents.20 The number of days needed to find the
effective dose was also recorded.
Statistical Analysis
Statistical analysis of quantitative and qualitative data,
including descriptive statistics, was performed for all
items. Frequency analysis was performed with chi-square
test or Fisher’s exact test, as needed for categorical
variables. The paired Wilcoxon signed-rank test and
paired samples Student’s t-test were used to compare
symptom intensity and opioid dosage, respectively, at the
different intervals. The one-way analysis of variance
(ANOVA) and Kruskal–Wallis test were used for para-
metric and nonparametric analysis, respectively, to
evaluate differences between the groups. Spearman’s
rho analysis was used to test for a correlation between
pain intensity at different intervals. Multinomial logistic
regression analysis examined the correlation between
different pain outcome (dependent variable) and various
patient characteristics. Data were analyzed by the Epi
Info software (version 6.0; Centers for Disease Control
and Prevention, Atlanta, GA, U.S.A.) and IBM SPSS
Software 21.0 version (SPSS, Inc., Chicago, IL, U.S.A.).
All P-values were two-sided, and P-values < 0.05 were
considered statistically significant.
RESULTS
The characteristics of patients are described in Table 1.
Data from 8 patients were incomplete or unavailable
(Figure 1). Data with outcomes were available in 166 of
174 patients having a pain intensity of > 4/10 at T0. The
mean age was 65.1 year (SD 11.9), and 70 patients were
Table 1. Characteristics of Patients and Categories of
Response
a b c d
Age (mean and SD) 69.8
(11.6)
65.8 (12.0) 62.3 (11.6) 68.7 (3.8)
Gender (M/F) 17/27 14/21 38/46 1/2
Primary tumor
Lung 7 6 23 1
Breast 9 9 13 0
Urogenital 9 4 15 2
Gastrointestinal 4 7 7 0
Pancreas 4 3 6 0
Head and neck 3 1 4 0
Others 8 5 16 0
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males. The primary diagnoses were in a rank order: lung
(n. 37), breast (n. 31), urogenital (n. 30), gastrointestinal
(n. 18), pancreas (n. 13), head & neck (n. 8), myeloma
(n. 7), liver (n. 5), other (n. 17). One hundred and seven
patients (64%) had an incident bone pain, 12 patients
(7.2%) had a positive CAGE, and 11 patients (6.6%)
had a positive CAM. Twenty-one (12.7%) patients had
values of PainDETECT of > 18 (neuropathic compo-
nent is likely). The mean pain-DETECT value for all
patients was 8.9 (SD 7.6).
Table 2 reports pain intensity data and opioid doses
at admission (T0), at T-15, and at time of stabilization
after opioid titration (Ts). At T-15 and T0, the mean
pain intensities were 6.3 (SD 1.5) and 6.7 (SD 1.2),
respectively. There was a close correlation between the
mean pain intensity at T-15 and at T0 (P < 0.0005;
Spearman’s rho correlation test). Forty-four, 35, and 84
patients had a response “a”, “b”, and “c”, respectively.
Most of the patients in category “c” (80 patients, 95%)
underwent an opioid switching.
Age predicted the analgesic response (worse in
younger patients (age < 65 years), P = 0.003), while
gender did not influence the response (P = 0.735). A
severe pain intensity (≥ 7/10), at T0 and at T-15, and an
OEImg > 5 were more often reported in category c
(P = 0.008, 0.020, 0.004, respectively) (Table 2). In the
analysis of frequency and continuous variables, CAGE,
CAM, pain-DETECT, incident pain, and psychological
distress were not different in the different categories of
response (Tables 2 and 4). Changes in ESAS items are
reported in Table 3. All the values of ESAS items
statistically improved 1 week after the treatment
(P < 0.0005). The mean OEI% and OEImg were 18.8
(SD 51.6) and 2.3 (SD 20.8), respectively. Pain intensity
at T0, but not at T-15, was correlated with response
categories (P = 0.05 and P = 0.07, respectively). There
was a significant relation between duration of opioid
therapy with ≥ 60 mg oral morphine equivalents before
admission and categories of pain response (P = 0.001)
(Table 4).
Multinomial logistic regression analysis is shown in
Table 5. Both pain intensity or pain intensity ≥ 7/10, at
either T0 or T-15, were correlated with the need of more
complex treatments (category c). Age (< 65 years),
duration of opioid therapy at doses ≥ 60 mg of oral
morphine equivalents, doses of oral morphine equiva-
Figure 1. Flow diagram of patients included in the study.
Table 2. Number of Patients with Positive CAGE, Positive
CAM, Positive Pain-DETECT, Incident Pain, Psychological
Distress, Pain Intensity > 7/10 at T0 and T-15, and
OEImg > 5, in the Different Categories of Response (“a”,
“b”, and “c”)
a b c P
CAGE positive 4 1 7 0.509
CAM positive 2 2 7 0.693
PAIN DETECT positive(> 18) 7 3 11 0.624
Incident pain 26 25 53 0.516
Psychological distress > 10 10 5 14 0.577
Pain intensity T0 > 7 4 10 29 0.008
Pain intensity -15 > 7 3 10 21 0.020
OEImg >5 11 21 35 0.004
Table 3. Symptoms Recorded with ESAS, OEI%, OEImg,
and Oral Morphine Equivalents at T0 and Ts (See Text)
T0 Ts P
Pain intensity 6.7 (1.2) 2.2 (0.9) < 0.0005
Weakness 5.2 (2.4) 4.0 (2.2) < 0.0005
Nausea 1.5 (2.1) 0.5 (1.3) < 0.0005
Appetite 4.0 (2.8) 3.1 (2.5) < 0.0005
Anxiety 3.4 (2.4) 2.4 (2.0) < 0.0005
Depression 3.3 (2.5) 2.5 (2.3) < 0.0005
Drowsiness 1.7 (2.2) 1.2 (1.7) 0.005
Dyspnea 0.8 (1.5) 0.5 (1.1) < 0.0005
Well-being 5.5 (1.7) 4.3 (1.6) < 0.0005
Total ESAS 27.1 (9.0) 20.5 (9.8) < 0.0005
OEI% – 18.8 (51.6)
OEImg – 2.3 (20.8)
Oral morphine equivalents 121 (173) 136 (130) 0.164
Table 4. Continuous Variables for Categories of
Response (Univariate Analysis of Variance – ANOVA Test)
Outcome
Pain DETECT P = 0.707
CAGE P = 0.727
Pain intensity at T0 P = 0.05
Psychological distress P = 0.498
Mean Pain intensity -15 P = 0.070
Duration opioid therapy P = 0.001
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lents at T0, OEImg > 5, as well as days for dose finding,
were associated with more complex treatments.
Only 3 patients (1.8%) had a response “d” (poor pain
control/prevalent adverse effects) after 1 week of treat-
ment and were not considered for statistical purposes.
These patients had a mean pain intensity at T0 and T-15
of 7.7 (SD 0.6) and 7.5 (SD 0.7), respectively, and an
OEImg of 32.4 (SD 31.4) and OEI% of 11.3 (SD 0.14),
respectively. Two patients had a pain intensity ≥ 7/10 at
T0. All patients had incident pain and pain intensity at
T-15 ≥ 7/10.
DISCUSSION
The principal finding of this study was that pain
intensity recorded at time of admission influences the
analgesic response to a timely and standardized analge-
sic treatment. The efficacy of the analgesic treatment is
evidenced by the improvement of pain intensity and
symptoms, as recorded by the changes in ESAS. In fact,
almost all patients (163/166, 98.1%) achieved adequate
pain control with acceptable opioid-related symptoms
within 1 week.
However, we also observed that there was a corre-
lation between pain at T0 and pain at T-15 and
categories of response, confirming that patients with
prolonged uncontrolled pain are likely to need more
complex treatments such as aggressive symptomatic
therapies and opioid/route switching, although not
necessarily a bad prognosis. In fact, most patients
achieved an acceptable analgesia within 1 week with
an appropriate and timely use of opioids.
In a secondary analysis of prospectively collected data
from a multicenter study for classifying advanced cancer
patients with pain, the initial pain intensity has been
indicated as a contributing factor in requiring a longer
time to achieve stable pain control, high final opioid
doses, and more complicated analgesic regimes.5
In a subsequent multicenter study of unselected
patients referred to palliative care, pain intensity was
independently associated with pain prognosis, in terms
of days to achieve stable pain control.3 In a further
secondary analysis of data of an epidemiological study
on the pattern and quality of cancer pain management,
pain intensity was found to predict pain outcome after
2 weeks.4 Original data from these studies, however,
showed that undertreatment in the longitudinal part of
the study strongly biased the outcome, as treatments
were nonstandardized and probably nonoptimized.7
The method of titration and consequently the median
length of time to achieve stable pain control in patients
with moderate–severe pain required a median of 8 to
22 days, with small dose increments of opioids.5 The
initial pain intensity is a relative concept, as it depends
on the time the patient is intercepted in its trajectory
along the course of disease.21 Indeed, several surveys
and also daily practice in experienced palliative care
centers suggest that pain control is obtained in a few
days in most patients using an adequate opioid dose
titration.8,9,11 Thus, one could argue that different
settings could have used different procedures of opioid
titration, or that no established protocol was planned in
multicenter studies performed in different centers. In a
secondary analysis of patients treated with similar
protocols, initial pain intensity did not predict the
outcome after an appropriate opioid titration.10
Our hypothesis was that pain intensity at time of
examination cannot be considered “per se” as a well-
defined factor predictive of a poor analgesic response,
along the course of pain trajectory, as it depends on
referral characteristics, for example, treatment behavior
on behalf of previous teams or GPs, rather than on pain/
patient characteristics. Alternately, the level of opioid
tolerancemay play a role. The reasons rely on the clinical
experience of patients who are often undertreated at
referral (they present high pain intensity and receive
inadequate therapy). They then respond to adequate
changes of therapy, in some case, just minimal increases
Table 5. Multinomial Logistic Regression Analysis
Parameter
Multinomial Logistic Regression
Exp(B) 95% CI P
Mean pain intensity a T0 1.45
1.38
1.01 to 2.10
1.02 to 1.86
0.05*
0.035†
Pain intensity ≥ 7 a T0 4.0
5.3
1.13 to 14.13
1.71 to 16.19
0.031*
0.004†
Mean pain intensity a -15 1.46
1.18
1.05 to 2.03
0.92 to 1.51
0.025*
0.202
Pain intensity ≥ 7 a -15 5.6
4.9
1.38 to 22.21
1.37 to 17.58
0.015*
0.014†
Age 0.97
0.94
0.93 to 1.0
0.91 to 0.98
0.127
0.001†
Duration of opioid therapy
(> 60 mg/day of oral
morphine equivalents)
0.87
1.63
0.59 to 1.28
1.23 to 2.16
0.479
0.001†
Oral morphine
equivalents T0
0.99
1.0
0.98 to 0.99
1.01 to 1.02
0.020*
0.020†
Days of dose finding 1.49
2.24
1.03 to 2.17
1.59 to 3.15
0.033*
< 0.0005†
OEImg > 5 5.09
2.12
1.89 to 13.64
0.94 to 4.77
0.001*
0.069
OEI% 1.03
1.01
0.99 to 1.05
0.98 to 1.03
0.059
0.334
*“a” vs. “b” category.
†“a” vs. “c” category.
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in opioid doses. Thus, a poor analgesia may result from a
development of tolerance or a progression of disease
unbalanced by timely changes of the treatment.
We designed the study to ascertain the role of lasting
undertreatment or poor analgesia at time of admission
to palliative care units. Moreover, we restricted the
selection of patients to a group with a level of pain
requiring changes in analgesic treatment, commonly
based on moderate–sever pain (> 4/10). The presence of
a group of patients, who would not change the
treatment because they already have well controlled
pain, could interferes with the outcome, often based on
the time needed to find a good balance between
analgesia and adverse effects.3,5 We also considered
1 week as an acceptable cut-off for opioid titration or
changes in pain management.8,10,11 This finding was
confirmed even stratifying the patients according to the
level of pain intensity: patients with severe pain intensity
(≥ 7/10) at T-15 and T0 more frequently required
aggressive symptomatic treatment or opioid/route
switching than patients with moderate pain. This finding
is consistent with the observation that patients with
severe pain are likely to be admitted within 30 days.22
Younger patients (< 65y) most frequently required
complex therapies. This finding confirms previous
observations.3,4 As expected, OEI was related with the
categories of response. This score, however, should not
be considered as a prognostic factor but as a means to
evaluate the analgesic response.20,23 Of interest, the
doses of opioids used at T0 were correlated to the
analgesic response. In pioneer studies, the level of
tolerance was initially considered to be a predictive
factor.1 This factor has been removed from subsequent
pain classification systems.24 Instead, it is likely that
when eliminating the range of patients with mild pain or
no pain, the duration of treatment with ≥ 60 mg of oral
morphine equivalents may influence the outcome of
patients with moderate–severe pain intensity. Similarly,
patients receiving higher doses of oral morphine equiv-
alents may require more aggressive pharmacological
treatments more often. Patients who have been treated
with higher doses opioids or for prolonged periods of
time may require further dose escalation, possibly
producing adverse effects and the need of opioid
switching. It has been found that integrated outcome
of pain score and opioid consumption may provide a
mean for integrated analgesic assessment.25 This issue
deserves further investigation.
Other aspects regarding previous factors taken into
consideration for the pain outcome have been consid-
ered. The poor correlation between other factors, such as
CAGE, CAM, neuropathic pain, and incident pain,
commonly included in the analysis of pain prognosis,
and pain response reported in this study, is explainable
by the low number of patients having the predictive
factors taken into consideration. Despite a higher num-
ber of patients with positive CAGE, CAM, painDE-
TECT, psychological distress, measured with 2 specific
items of ESAS, and incident pain were found in category
“c”, this data did not attain statistical significance.
Moreover, the selection of patients having poor pain
control at time of initial evaluation possibly flattened the
data. In fact, patients with adequate pain control were
not included in the study, as they do not require further
refinements of the analgesic therapy. Finally, patients
with uncontrolled pain had clearly distinguishable
superimposed pain, explaining the figures regarding
breakthrough pain, and, specifically, incident pain due
to movement. In fact, almost all patients presented
episodes of breakthrough pain. Although this should not
be exactly considered according to basic definition, it has
been reported that patients with uncontrolled pain are
more likely to develop breakthrough pain.26
This article may have some limitations. Patients were
recruited in 2 palliative care units and the findings
cannot be extended to other settings. These units have
been sharing protocols and research projects for many
years. Treatments are quite homogeneous and not
significantly variable between treating physicians. The
homogeneity of treatments providing an adequate pain
control in most cases in a few days should be considered
as a standard of any specialistic palliative care setting.
This approach may provide a better guarantee regarding
the data, as multicenter studies with large number of
patients but different modalities of intervention, may
more often provide less reliable data.27
The second aspect regards the recall of pain inten-
sity 15 days before admission. However, there is no
way to intercept a patient before the admission, unless
selecting patients and leaving them without allowing
an analgesic intervention. From the practical and
ethical point of view, this would have been quite
problematic. Moreover, in patients with cancer pain,
recall ratings have been found to be reliable as outcome
measures in clinical trials.28
Finally, the number of patients who were considered
unresponsive after an intensive treatment of 1 week
(category “d”) was quite low to extrapolate useful
information. Thus, the risk factors individualized in
this study regard patients requiring more complex
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treatments (category c), but not necessarily those who
have a negative prognosis. A more aggressive treatment
with opioids in an appropriate setting, including strict
assessment and monitoring while titrating opioid doses,
or changing opioid or route of administration, may
significantly improve the opioid response. Meaning,
regardless of possible interfering factors, almost all
patients with cancer may achieve a good balance of
analgesia and adverse effects with an appropriate
analgesic treatment in a specialized setting of palliative
care.29
In conclusion, the level pain intensity at admission
requires a more aggressive treatment for patients with
cancer with moderate–severe pain intensity who require
changes in analgesic treatment. This level of pain
intensity is long lasting due to a previous undertreat-
ment, as it is related to level of pain intensity recalled
15 days before. Similarly, opioid doses, duration of
opioid therapy, and younger age may require more
aggressive treatment. In this group of patients, other
factors previously reported to influence the outcome
seem to have less importance, possibly because the lack
of a comparator group with mild pain. However, this
level of pain does not usually require changes in
analgesic treatment and cannot be discriminative.
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